Berkley E. Gryder
Affiliations: | Genetics and Genome Sciences | Case Western Reserve University, School of Medicine |
Website:
https://case.edu/medicine/genetics/people/primary-faculty/berkley-gryderGoogle:
"Berkley Gryder"Bio:
http://hdl.handle.net/1853/52926
Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Adegboyega K. Oyelere | grad student | 2013 | Georgia Tech | |
| (New insights into targeting the androgen receptor for cancer therapy: from selective delivery of gold nanoparticles and histone deacetylase inhibitors, to potent antagonists and inverse agonists) | ||||
Children
Sign in to add trainee
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Garzón-Porras AM, Chory E, Gryder BE. (2022) Dynamic Opposition of Histone Modifications. Acs Chemical Biology |
| Ohguchi H, Park PMC, Wang T, et al. (2021) Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma. Blood Cancer Discovery. 2: 370-387 |
| Adelaiye-Ogala R, Gryder BE, Nguyen YTM, et al. (2020) Targeting the PI3K/AKT pathway overcomes enzalutamide resistance by inhibiting induction of the glucocorticoid receptor. Molecular Cancer Therapeutics |
| Gryder BE, Wu L, Woldemichael GM, et al. (2019) Chemical genomics reveals histone deacetylases are required for core regulatory transcription. Nature Communications. 10: 3004 |
| Gryder BE, Akbashev MJ, Rood MK, et al. (2013) Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors. Acs Chemical Biology. 8: 2550-60 |
| Gryder BE, Rood MK, Johnson KA, et al. (2013) Histone deacetylase inhibitors equipped with estrogen receptor modulation activity. Journal of Medicinal Chemistry. 56: 5782-96 |
| Dreaden EC, Gryder BE, Austin LA, et al. (2012) Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells. Bioconjugate Chemistry. 23: 1507-12 |
| Gryder BE, Sodji QH, Oyelere AK. (2012) Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Medicinal Chemistry. 4: 505-24 |
| Patil V, Guerrant W, Chen PC, et al. (2010) Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group. Bioorganic & Medicinal Chemistry. 18: 415-25 |